The new Affymax (NASDAQ: AFFY) is building upon its proven discovery platform and extensive pharmaceutical experience to build a pipeline of peptide drugs to treat cancer and immune-mediated diseases. The powerful combination of broad management experience, clinical development know-how, a proven drug discovery engine and strong intellectual property, positions Affymax as a preeminent drug discovery and development company. The Company has been a pioneer in chemistry and high throughput screening technologies that enable faster and more efficient processes for drug discovery by integrating proprietary chemistries, innovative molecular biology techniques, sophisticated software and instrumentation technology.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 04/11/06 | Series E | 10M | Benchmark Capita, Ventech Capital, Shotput Ventures, Jay Adelson, Greenwich Technology Associates, Apex Venture Partner, Coyne Group, LLC, Atomico Ventures, Comtex, Jim Bankoff, Santander Bank, SRIW, EVS Broadcast Equipment, Central American Bank for Economic Integration | Unknown |
People
Kay Slocum (SVP Human Resources)
Christopher Dammann (VP Business Development)
R. Douglas (Board Member)
Peter Young (VP Research)
Douglas Cole (VP Development)
News
Public biotech firms Cadence, Affymax draw $128M from bargain-hunting VCs
February 18, 2009 5:56 pm
Much has been written about how the IPO market froze out biotech companies in 2008, but it looks like times… Continue reading ⟩
Roundup: Anemia drugs under assault, stem-cell trial moves forward, medical interventions and poor "quality of death," and more
May 11, 2007 12:51 am
Is the bell tolling for EPO? – The news keeps going from bad to worse for the wonder drugs of… Continue reading ⟩
Drug maker Affymax to issue shares, despite doubling losses
December 1, 2006 6:33 pm
Affymax, a Palo Alto biotech company that makes synthetic peptide-based drugs to treat kidney diseases and cancer, is planning an… Continue reading ⟩